Found: 5
Select item for more details and to access through your institution.
iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2005, doi. 10.1111/dom.15074
- By:
- Publication type:
- Article
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2182, doi. 10.1111/dom.14803
- By:
- Publication type:
- Article
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1522, doi. 10.1111/dom.14722
- By:
- Publication type:
- Article
Cover Picture: Astron. Nachr. 11/2022.
- Published in:
- Astronomische Nachrichten, 2022, v. 343, n. 9/10, p. 1, doi. 10.1002/asna.20229013
- By:
- Publication type:
- Article
Yunnan–Hong Kong wide field photometric survey.
- Published in:
- Astronomische Nachrichten, 2022, v. 343, n. 9/10, p. 1, doi. 10.1002/asna.20224022
- By:
- Publication type:
- Article